12/01/2012
Anapharm Europe acquires a new high sensitivity equipment
The new equipment allows the determination of extremely low concentration of compounds such as Fluticasone, Salmeterol, Budesonide, Formoterol, Tiotropium, Ethinyl Estradiol, Paricalcitol, etc. In biological fluids.
As part of its efforts to continue to support drug development of women health and inhaler products, Anapharm Europe has purchased a new equipment targeted for method validation with limits of quantification in the low pg/mL level. The AB SCIEX QTRAP 5500 increases our capabilities for the determination extremely low concentrations of compounds such as Fluticasone, Salmeterol, Budesonide, Formoterol, Tiotropium, Ethinyl Estradiol, Paricalcitol, etc. in biological fluids.
MORE NEWS
Anapharm Bioanalytics’ successful FDA Inspection
Anapharm Bioanalytics is proud to announce that it has successfully undergone another US FDA inspection at its Barcelona based bioanalytical lab. The inspection, that took place in June 2019, had a focus on a total of 8 studies. This was the second unannounced FDA inspection at our facilities without any observations; no 483 form issued.
READ MOREAnapharm Bioanalytics has been acredited under the Gulf Health Council
Anapharm Bioanalytics is proud to announce that it has been recently added to the List of Bioequivalence Centres Approved by GCC, Gulf Cooperation Council (United Arab Emirates, Bahrain, Kingdom of Saudi Arabia, Sultanate of Oman, Qatar, Kuwait and Republic of Yemen).
READ MOREAnapharm Bioanalytics Brazilian ANVISA Certificate Renewal
Anapharm Bioanalytics is proud to announce that it has recently renewed its ANVISA (Brazil) certificate.
The renewed certification is valid until 11th June 2020.